Your Article Summary
See Latest ArticlesPopulation-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer
BJU International, 06/25/09
Moore AL et al. – Study reports that population-based prostate specific antigen (PSA) testing resulted in a significant downward stage and grade migration, and most such cancers were of low stage and grade, which could lead to risks of over-treatment for some men.
Methods- Aim was to determine the stage and grade of PCa that would be found through population-based PSA testing and biopsy in UK
- Men aged 50–69 yrs from 9 cities in the UK and from randomly selected practices of general practitioners (ProtecT)
- Those with a PSA level of >3 ng/mL were offered a prostate biopsy
- Age, PSA, stage and grade at diagnosis of ProtecT participants with cancer were compared with contemporaneous incident cases aged 50–69 yrs registered at ECRIC
- Within ProtecT, 94,427 men agreed to be tested (50% of men contacted):
- 8,807 (~9%) had a raised PSA level
- 2,022 (23%) had prostate cancer
- 229 (~12%) had locally advanced (T3 or T4) or metastatic cancers
- Rest had clinically localized (T1c or T2) disease
- Within ECRIC, 12,661 cancers were recorded over the same period; 3714 were men aged 50-69 yrs at diagnosis
- Men in ProtecT had a lower age distribution and PSA level, and the cancers were of lower stage and grade
- If population-based PSA testing were introduced in the UK, ~2660 men per 100,000 aged 50-69 yrs would be found to have PCa, vs current rates of ~130 per 100,000
- If half of men accepted PSA testing, ~160,000 cancers would be found, compared to 30,000 diagnosed each year at present
Related Articles
Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage
Rheumatology International, 10/28/09
Relevance Score: 63%
Nodal staging score: A tool to assess adequate staging of node-negative colon cancer
Journal of Clinical Oncology, 11/16/09
Relevance Score: 48%
Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: A study of 241 patients
Cancer Investigation, 11/16/09
Relevance Score: 46%
Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma
Cancer, 10/26/09
Relevance Score: 46%
Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator Spirometry
Yonsei Medical Journal, 10/23/09
Relevance Score: 46%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Patient Perceived Effectiveness of a New Male Sling as Treatment for Post-Prostatectomy Incontinence
The Journal of Urology, 12/18/09
Health-related quality of life in men with localized prostate cancer
International Journal of Urology, 12/18/09
Today in Radiology/Diagnostics...keeping you current
Receive free subspecialty "5-minute updates" via email
Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles
The Prostate, 12/18/09
Influence of Cytokine Gene Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer after Radical Prostatectomy
Urologia Internationalis, 12/18/09
Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence
Medical Oncology, 12/18/09